Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: A case series

Medical Science Monitor

Volumn 10, Issue 8, 2004, Pages

  Lehmann, Andreas ^a,b   Lang, Johannes ^a   Boldt, Joachim ^a   Isgro, Frank ^a   Kiessling, Arndt Holger ^a  

^a Municipal Hospital   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Cardiac surgery; Cardioprotection; Inoprotection; Ischemia

Indexed keywords

CATECHOLAMINE; INOTROPIC AGENT; LEVOSIMENDAN; NORADRENALIN;

ADULT; AGED; AORTA BALLOON; ARTICLE; ARTIFICIAL VENTILATION; BOLUS INJECTION; CARDIOGENIC SHOCK; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MECHANISM; FEMALE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MALE; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDY; RESUSCITATION; REVASCULARIZATION; VASODILATATION; WEANING;

ADULT; AGED; CARDIOTONIC AGENTS; DOPAMINE; FEMALE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; NOREPINEPHRINE; PYRIDAZINES; SHOCK, CARDIOGENIC; VASCULAR SURGICAL PROCEDURES; VASOCONSTRICTOR AGENTS;

EID: 4444226530     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Haikala H, Pollesello P: Calcium sensitivity enhancers. IDrugs, 2000; 3: 1199-205
2. Lehtonen LA: Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs, 2001; 10: 955-70
3. Kersten JR, Montgomery MW, Pagel PS, Warltier DC: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels. Anesth Analg, 2000; 90: 5-11
4. Holubarsch C: New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology, 1997; 88(Suppl.2): 12-20
5. Adams HA, Baumann G, Gansslen A et al: Definition of shock types. Anaesthesiol Intensivmed Notfallmed Schmerzther, 2001; 36(Suppl.2): S140-S143
6. Haikala H, Kaivola J, Nissinen E et al: Cardiac troponin C as a target protein for novel calcium sensitizing drug, levosimendan. J Moll Cell Cardiol, 1995; 27: 1859-66
7. Lillleberg J, Nieminen MS, Akkila J et al: Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J, 1998; 19: 660-68
8. Kaheinen P, Pollesello P, Levijoki J, Haikala H: Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol, 2001; 37: 367-74
9. + channel in rat ventricular cells. J Pharmacol Exp Ther, 1997; 283: 375-83
10. Kopustinskiene DM, Pollesello P, Saris NE: Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol, 2001; 428: 311-14
11. Loubani M, Galinanes M: Pharmacological and ischemic preconditioning of the human myocardium: mitoKATP channels are upstream and p38MAPK is downstream of PKC. BMC Physiol, 2002, 2: 10
12. Perrault LP, Menasche P: Preconditioning: can nature's shield be raised against surgical ischemic-reperfusion injury? Ann Thorac Surg, 1999; 68: 1988-94
13. Patel DJ, Purcell HJ, Fox KM: Cardioprotection by opening of the K(ATP) channels in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J, 1999; 20: 51-57
14. Stadnicka A, Bosnjak ZJ: Isoflurane decreases ATP sensitivity of guinea pig cardiac sarcolemmal KATP channel at reduced intracellular pH. Anesthesiology, 2003, 98: 396-403
15. Zaugg M, Lucchinetti E, Spahn DR et al: Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channel via multiple signaling pathways. Anesthesiology, 2002; 97: 4-14
16. Cope DK, Impastato WK, Cohen MV, Downey JM: Volatile anesthetics protect ischemic rabbit myocardium from infarction. Anesthesiology, 1997; 86: 699-709
17. Hochman JS, Sleeper LA, Webb JG et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med, 1999; 341: 625-34
18. Hasenfuss G, Pieske B, Castell M et al: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 1998, 98: 2141-47
19. Hasenfuss G, Pieske B, Kretschmann B et al: Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol, 1995, 26(Suppl.1): S45-S51
20. Lehmann A, Boldt J, Lang J et al: Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization? Anaesthesiol Intensivmed Notfallmed Schmerzther, 2003; 38: 577-82
21. Thompson CR, Buller CE, Sleeper LA et al: Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol, 2000; 36(3 Suppl.A): 1104-9
22. Muller M, Junger A, Brau M et al: Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anaesthesia record-keeping system. Br J Anaesth, 2002, 89: 398-404
23. Nijhawan N, Nicolosi AC, Montgomery MW et al: Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol, 1999, 34: 219-28
24. Moiseyev VS, Poder P, Andrejevs N et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J, 2002; 23: 1422-32
25. Lethonen L: Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep, 2000; 2: 233-43